I wondered when this would happen. Reminds me of the video game “The Last of Us” and there’s a TV series as well. I’m sure they’ll stop it though.
Silver leaf disease is a curse for a variety of botanicals, from pears to roses to rhododendron. Infecting their leaves and branches, the fungus Chondrostereum purpureum can be fatal for the plant if not quickly treated.
Aside from the risk of losing the occasional rose bush, the fungal disease has never been considered a problem for humans. Until this year.
In what researchers suggest is the first reported case of its kind, a 61-year-old Indian mycologist appears to have contracted a rather serious case of silver leaf disease in his own throat, providing a rare example of a pathogen seemingly making an enormous leap across entire kingdoms in the tree of life.
Humanity is slowly losing access to the night sky, and astronomers have invented a new term to describe the pain associated with this loss: “noctalgia,” meaning “sky grief.”
Along with our propensity for polluting air and water and the massive amounts of carbon we’re dumping into the atmosphere to trigger climate change, we have created another kind of pollution: light pollution.
The US has embarked on a program to develop electronic-warfare drone swarms, the latest in its multiple projects to master what could potentially be war-winning AI and drone technology, though with significant operational and strategic implications and risks.
This month, Breaking Defense reported that the US Navy is seeking industry and government agencies to participate in a July 2024 exercise called Silent Swarm 2024, which aims to demonstrate early-stage unmanned systems’ capabilities to fight on the electromagnetic battlefield.
Breaking Defense notes that the event, hosted by Naval Surface Warfare Center Crane, will showcase “swarming, small, attritable” unmanned systems capable of distributed electromagnetic attack, deception, and digital payload delivery, with the tech must be within readiness levels (TRL) two to five, with higher numbers indicating more advanced systems.
Jason Shawhan, Tesla’s director of manufacturing at Giga Texas, recently gave a rare talk about the facility’s existing operations and the company’s plans for the future. The executive shared the information during a keynote address at the State of Manufacturing conference and expo, which was held by the Austin Regional Manufacturers Association.
Tesla is the world’s most valuable automaker by market cap, and its CEO, Elon Musk, is one of the most visible chief executives in the auto industry. Despite this, Tesla has a reputation for being tight-lipped when it comes to the details of its operations. Rare appearances from high-ranking executives such as Shawhan, who serves as director of manufacturing at Gigafactory Texas, are therefore very interesting.
Shawhan did not disappoint, as he did share a number of important insights about the facility. As noted in a report from the Austin Business Journal, the executive confirmed that Giga Texas has become the second-largest private employer in the region because the factory currently employs over 20,000 workers today. This is a notable increase from the 12,277 employees that Tesla confirmed at the end of 2022. Considering Gigafactory Texas’ growth so far, it would appear that the facility would be outpacing Musk’s estimates.
It could be a new way to treat one of the more common and more frustrating symptoms of Alzheimer’s. A team at Johns Hopkins is leading a study on the drug, and you can get involved.
Leveraging Technology For Innovative, Patient-Centered Clinical Care — Dr. Peter Fleischut, MD — Group Senior Vice President And Chief Information & Transformation Officer, NewYork-Presbyterian Hospital
Dr. Peter M. Fleischut, M.D., is Group Senior Vice President and Chief Information and Transformation Officer at NewYork-Presbyterian (https://www.nyp.org/)where he oversees the strategic vision and management of enterprise information technology, lab operations, pharmacy operations, innovation, data and analytics, artificial intelligence, telemedicine, and cybersecurity.
Dr. Fleischut has led the development of the Hospital’s award-winning digital health services and the implementation of clinical operations at NewYork-Presbyterian David H. Koch Center, a world-class ambulatory care center. In his previous role as Senior Vice President and Chief Transformation Officer, he focused on creating a single electronic medical record across NewYork-Presbyterian and its affiliated medical schools, Weill Cornell Medicine and Columbia University Vagelos College of Physicians and Surgeons.
Dr. Fleischut also led efforts to standardize care across NYP’s ten hospitals and hundreds of clinics and doctor practices, and oversaw all aspects of Graduate Medical Education (GME) for programs across the NYP enterprise.
Joining NewYork-Presbyterian/Weill Cornell in 2006, Dr. Fleischut previously served as Medical Director of Operating Rooms, Deputy Quality Patient Safety Officer, founding Director of the Center for Perioperative Outcomes, Vice Chairman, Chief Medical Information Officer, Chief Innovation Officer and Chief Medical Operating Officer.
Revolutionizing Musculoskeletal Health Through Microcapsule Drug Delivery — Dr. @George R. Dodge, Ph.D. — CEO & Co-Founder — Mechano-Therapeutics LLC
Dr. George R. Dodge, Ph.D. is CEO & Co-Founder of Mechano-Therapeutics LLC (https://mechano-therapeutics.com/), a biotechnology company spun out from his lab, and the labs of his partners Dr. Rob Mauck and Dr. Daeyeon Lee, at the University of Pennsylvania, specializing in microcapsule development using proprietary microfluidics for drug encapsulation, with a mission to revolutionize musculoskeletal health using an innovative platform technology to enhance delivery of therapeutics for improving patient outcomes.
Dr. Dodge recently served on the faculty of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania; as Director, Philadelphia VA Shared Instrument Core; and Director, Translational Musculoskeletal Research Center, Philadelphia Crescenz Veterans Administration Medical Center, Department of Veteran Affairs.
Dr. Dodge has a B.S. (Biology) from Asbury College, a B.S. (Biology and Health Science / Public Health) from State University of New York, a Ph.D. (Biochemistry and Immunology) from McGill University, and did Post-Graduate work in Molecular and Cell Biology, at Thomas Jefferson University Department of Pathology and Cell Biology.
Dr. Dodge is an established investigator with a career long commitment to translational musculoskeletal research and in particular research focused on cartilage and chondrocyte biology, extracellular matrix and research related to osteoarthritis.
